The Potential of High Sensitivity Diagnostic Immunoassay Testing: Current Benefits and Future Capabilities

Sept. 18, 2024
Join Drs. Christenson and Levy as they explore the groundbreaking potential of high sensitivity diagnostic immunoassay testing. Learn how these advancements are shaping the future of cardiac care and beyond.

Date: Wednesday, September 18, 2024 
Time: 1:00 PM ET / 12:00 PM CT / 10:00 AM PT 
Duration: 1 Hour

Already registered? Click here to log in.

Summary

A conversation between Drs. Robert H. Christenson and Phillip Levy considering the utility and impact of high sensitivity technologies in diagnostic immunoassay (IA) testing. Drs. Christenson and Levy will discuss the evolution and future of diagnostic IA testing and the benefits of increased sensitivity in cardiac care and beyond.


Speakers

Dr. Levy is the Edward S Thomas endowed Professor of Emergency Medicine at Wayne State University serving as the Associate Vice President for Translational Sciences, and the Director of the Wayne Health Mobile Unit Program, which he founded in April 2020. As a leading health equity researcher, Dr. Levy has overseen over 100 clinical studies focusing on cardiovascular disease risk reduction and brings extensive expertise in deep community phenotyping using integrated, multidimensional data and design as well as execution of targeted intervention programs. He is a fellow of multiple professional societies and serves as the Inaugural Chair for American College of Cardiology’s Accreditation Oversight Committee, a member of the College’s National Cardiovascular Data Registry Oversight Committee, and Vice Chair for the recently published AHA/ACC Guideline for Evaluation and Diagnosis of Chest Pain.

Dr. Christenson is professor of pathology and of medical and research technology at the University of Maryland School of Medicine in Baltimore. He heads the CCRL, a CLIA licensed and CAP accredited research lab specializing in government- and industry-sponsored clinical trials with an active program in cardiac and renal biomarkers. Clinically, he is medical director of Core Laboratories and point-of-care services at the University of Maryland Medical Center. He has served as chair of many AACC committees and as the association’s president. Dr. Christenson is very active in education and service worldwide. He received AACC’s 2023 Outstanding Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine and the IFCC’s 2023 Henry-Wishinsky Award for Distinguished International Service. He is currently Editor-in-Chief of the Journal of Applied Laboratory Medicine.

Sponsored by